Browse > Article
http://dx.doi.org/10.24304/kjcp.2020.30.3.169

Predictors of Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis  

Kim, Woorim (College of Pharmacy, Chungbuk National University)
Han, Ji Min (College of Pharmacy, Chungbuk National University)
Lee, Kyung Eun (College of Pharmacy, Chungbuk National University)
Publication Information
Korean Journal of Clinical Pharmacy / v.30, no.3, 2020 , pp. 169-176 More about this Journal
Abstract
Background: Most meta-analyses of risk factors for severe or critical outcomes in patients with COVID-19 only included studies conducted in China and this causes difficulties in generalization. Therefore, this study aimed to systematically evaluate the risk factors in patients with COVID-19 from various countries. Methods: PubMed, Embase, and Web of Science were searched for studies published on the mortality risk in patients with COVID-19 from January 1 to May 7, 2020. Pooled estimates were calculated as odds ratio (OR) with 95% confidence interval (CI) using the random-effects model. Results: We analyzed data from seven studies involving 26,542 patients in total in this systematic review and meta-analysis. Among the patients, 2,337 deaths were recorded (8.8%). Elderly patients and males showed significantly higher mortality rates than young patients and females; the OR values were 3.6 (95% CI 2.5-5.1) and 1.2 (95% CI 1.0-1.3), respectively. Among comorbidities, hypertension (OR 2.3, 95% CI 1.1-4.6), diabetes (OR 2.2, 95% CI 1.2-3.9), cardiovascular disease (OR 3.1, 95% CI 1.5-6.3), chronic obstructive pulmonary disease (OR 4.4, 95% CI 1.7-11.5), and chronic kidney disease (OR 4.2, 95% CI 2.0-8.6) were significantly associated with increased mortalities. Conclusion: This meta-analysis, involving a huge global sample, employed a systematic method for synthesizing quantitative results of studies on the risk factors for mortality in patients with COVID-19. It is helpful for clinicians to identify patients with poor prognosis and improve the allocation of health resources to patients who need them most.
Keywords
COVID-19; SARS-CoV-2; mortality; comorbidity; systematic review; meta-analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 2010;25(9):603-5.   DOI
2 Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88.   DOI
3 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.   DOI
4 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323(16):1574-81.   DOI
5 Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J 2020;55(5):2000547.   DOI
6 Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020;382(25):e102.   DOI
7 Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020;31(8):1088-9.   DOI
8 Nikpouraghdam M, Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol 2020;127:104378.   DOI
9 Richardson S, Hirsch J, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323(20):2052-59.   DOI
10 Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect 2020;81(2):e59-e61.   DOI
11 Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003;139(9):715-23.   DOI
12 Hong KH, Choi JP, Hong SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). Thorax 2018;73(3):286-9.   DOI
13 Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis 2005;41 Suppl 7:S504-S512.   DOI
14 Jin JM, Bai P, He W, et al. Higher severity and mortality in male patients with COVID-19 independent of age and susceptibility. Front Public Health 2020;8:152.   DOI
15 Hoffmann M, Kleine-weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-80.e8.   DOI
16 Chu KH, Tsang WK, Tang CS, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005;67(2):698-705.   DOI
17 Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193-9.   DOI
18 Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623-8.   DOI
19 Patel S, Velkoska E, Burrell L. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol 2013;40(8):551-9.   DOI
20 Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv 2020:2020.03.04.20031120
21 Sharif M, Chitsazian Z, Moosavian M, et al. Immune disorders in hemodialysis patients. Iran J Kidney Dis 2015;9(2):84-96.
22 van Dijk P, Jager K, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16(6):1120-9.   DOI
23 Foley R, Parfrey P, Sarnak M. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-S119.   DOI
24 Sarnak M, Jaber B. Mortality caused by sepsis in patients with endstage renal disease compared with the general population. Kidney Int 2000;58(4):1758-64.   DOI
25 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054-62.   DOI
26 Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934-43.   DOI
27 Schiffrin EL, Flack JM, Ito S, Muntner P, Wenn RC. Hypertension and COVID-19. Am J Hypertens 2020;33(5):373-4.   DOI
28 Knapp S. Diabetes and infection: Is there a link? - A mini-review. Gerontology 2013;59(2):99-104.   DOI
29 HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Available from https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHAstatement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp. Accessed May 8, 2020.
30 Banik GR, Alqahtani AS, Booy R, Rashid H. Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin 2016;31(1):81-4.   DOI
31 Geerlings S, Hoepelman A. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26(3-4):259-65.   DOI
32 Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J 2020;41(19):1798-800.   DOI
33 Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5):531-8.   DOI
34 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.   DOI
35 Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5(7):811-8.   DOI
36 Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9.   DOI
37 WHO. Coronavirus disease (COVID-19) situation dashboard. Available from https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd. Accessed August 27, 2020.
38 Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest 2009;39(7):618-25.   DOI
39 Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(6):1304-9.   DOI
40 Leung JM, Tiew PY, Mac Aogain M, et al. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology 2017;22(4):634-50.   DOI
41 Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology 2003;8 Suppl:S9-14.   DOI
42 Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020;12(7):6049-57.   DOI
43 WHO. Middle east respiratory syndrome coronavirus (MERSCoV). Available from https://www.who.int/emergencies/mers-cov/en/; 2019. Accessed Apr 9, 2020.
44 Torres-Salinas, D. Daily growth rate of scientific production on Covid-19. Analysis in databases and open access repositories. arXiv preprint arXiv:2004.06721.
45 Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81(2):e16-e25.   DOI
46 Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-8.   DOI